Welcome to our dedicated page for Takeda Pharm news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharm stock.
Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.
Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.
Takeda reported Q3 FY2020 financial results, highlighting a 3.6% revenue decline to JPY 2,427.5 billion, impacted by foreign exchange and divestitures. However, underlying revenue grew by 1.1%, driven by strong performances from ENTYVIO and TAKHZYRO. Operating profit surged by 120.7% to JPY 358.7 billion, while net profit rose by 320.8% to JPY 178.9 billion. The company confirmed its FY2020 guidance, anticipating growth acceleration. Takeda also achieved significant cost savings and divestitures, exceeding its $10 billion target. Positive R&D developments promise future growth potential.
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) announced the presentation of 14 abstracts from its Hematology portfolio at the Virtual EAHAD 2021 Congress. Key findings from the seven-year AHEAD study revealed that prophylactic antihemophilic factor (rAHF) significantly reduced annualized bleeding rates in severe hemophilia A patients compared to on-demand treatment. Additional research highlighted the effectiveness of switching to alternative treatments like rurioctocog alfa pegol and emicizumab. The studies underscore the importance of real-world evidence in hemophilia management, showcasing Takeda's commitment to innovation and patient care.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has completed the sale of TachoSil® Fibrin Sealant Patch to Corza Health for €350 million. This transaction allows Corza to acquire the necessary assets and licenses for TachoSil®, while Takeda retains the manufacturing facility in Linz, Austria, and will exclusively produce TachoSil® under a long-term supply agreement. The proceeds from this sale will aid in reducing Takeda's debt as part of a strategy to achieve a target of 2x net debt/adjusted EBITDA by FY 2023.
Takeda Pharmaceutical Company has finalized the sale of a portfolio of select products in Latin America to Hypera S.A. for $825 million USD. This divestment, initially announced in March 2020, includes over-the-counter and prescription products. Approximately 300 commercial employees will transition to Hypera, while Takeda will continue to manufacture these products. Proceeds from the sale aim to reduce debt, targeting a net debt/adjusted EBITDA ratio of 2x by 2023. This sale contributes to Takeda's broader strategy, having exceeded its $10 billion non-core asset divestiture target in 2020.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has revealed promising new data from a Phase 1/2 trial of mobocertinib (TAK-788) for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC). The results indicate a 35% confirmed objective response rate and a median duration of response of 17.5 months in platinum-pretreated patients. Despite a manageable safety profile, mobocertinib is not yet FDA-approved. Takeda plans to submit findings to regulatory agencies globally and will host an investor briefing on January 29.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced new findings from the Phase 1/2 trial of mobocertinib (TAK-788) for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC). The late-breaking results presented at the IASLC 2020 WCLC indicate a confirmed objective response rate (ORR) of 35% and a median duration of response (DoR) of 17.5 months in platinum-pretreated patients. Takeda plans to submit these data to regulatory authorities globally. Mobocertinib is not yet approved for this indication.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has achieved carbon neutrality in its value chain for fiscal year 2019. This milestone was reached through energy conservation, green energy procurement, and investment in verified carbon offsets. Takeda aims to reduce operational emissions by 40% by 2025 and achieve carbon neutrality by 2040. The company supports over 30 renewable energy projects across 12 countries, addressing 15 out of 17 UN Sustainable Development Goals. Recognized for its climate leadership, Takeda has been named on CDP’s 'A List' and Corporate Knights Global 100 Most Sustainable Corporations.
Takeda Pharmaceutical Company Limited (NYSE:TAK) has received recognition in the 2021 Access to Medicine Index, ranking sixth overall among 20 pharmaceutical companies. The company excelled in Governance of Access, R&D capacity, and health system strengthening. Notably, Takeda ranked first in Governance of Access and led the industry for R&D capacity building. Its initiatives focus on affordable access, assessed access strategies, and local healthcare programs, such as the Blueprint for Innovative Healthcare Access in Kenya and Rwanda, aimed at enhancing medicine accessibility.
Summary not available.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) provided a comprehensive update during the 39th Annual J.P. Morgan Healthcare Conference. CEO Christophe Weber highlighted Takeda's strong business resilience amid COVID-19 and outlined plans for revenue growth through an innovative pipeline, targeting JPY5 trillion ($47 billion) by FY2030. Key programs, including TAK-003 for dengue and TAK-755 for thrombotic thrombocytopenic purpura, are expected to contribute significantly to revenue. Takeda aims to maintain investment-grade credit ratings, with a focus on cost synergies and shareholder returns.